Life sciences sector at biggest risk of internal information leaks
Researchers have found that 33 percent of companies in the life sciences sector experienced an information leak within the last year.
List view / Grid view
Researchers have found that 33 percent of companies in the life sciences sector experienced an information leak within the last year.
The UK healthcare agency has issued an alert for Perrigo ranitidine products, recalling and quarantining certain batches.
According to research from the Indian Pharmaceutical Alliance, the country’s pharma sector has capacity to grow. This article investigates some of the goals, challenges and proposals the report sets out for the industry.
Within this issue is an analysis of the impacts that low temperature can have on protein aggregation, a discussion on maintaining the safety and quality of medicines when delivered using drones and an exploration of chromatographic techniques used to identify impurities in radiopharmaceuticals. Other articles focus on regulatory non-compliance, excipients…
The FDA has announced its support of a drug manufacturer rating system that would allow purchasers to identify which have the most reliable supply, in an effort to reduce shortages.
The FDA has released an additional NDMA testing method and has alerted the public to multiple voluntary recalls of ranitidine.
Research has found that up to 60 percent of results for medicines on search engines present potentially counterfeit pharmaceutical products.
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
The FDA has released a statement on their generic drug approvals in FY 2019, revealing a new record high breaking above last year.
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
Your Global Drug Development Organization For Analytical Laboratory Testing and Clinical Research.
The Joint Pharmaceutical Analysis Group held an event in London, discussing the testing of nitrosamine mutagenic impurities in pharmaceutical products and the next steps for manufacturers to take.
The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.
Torrent Pharmaceuticals has received a warning letter from the FDA for violating cGMP regulations at its manufacturing facility in India.
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.